Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction
TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics today announced topline results from a phase 2a program evaluating the company’s investigational therapy for the treatment of MGD.